Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

Pituitary. 2016 Oct;19(5):544-6. doi: 10.1007/s11102-015-0663-4.

Authors

Simon J B Aylwin¹, Istvan Bodi², Ronald Beaney³

Affiliations

¹ Department of Endocrinology, King's College Hospital, London, SE5 9RS, UK. simonaylwin@nhs.net.
² Department of Clinical Neuropathology, King's College Hospital, London, UK.
³ Department of Neuro-oncology, Guy's & St Thomas' Hospital Cancer Centre, London, UK.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Craniopharyngioma / drug therapy*
Craniopharyngioma / genetics
Craniopharyngioma / pathology
Female
Humans
Indoles / pharmacology
Indoles / therapeutic use*
Pituitary Gland / pathology
Pituitary Neoplasms / drug therapy*
Pituitary Neoplasms / genetics
Pituitary Neoplasms / pathology
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*
Vemurafenib

Substances

Antineoplastic Agents
Indoles
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf